No abstract

survey linear regressions were used to analyze prevalence of DAH using the different guidelines controlling for race and sex. Predictors of depression were analyzed using survey logistic regression models. Results: Preliminary analysis shows that the overall unadjusted prevalence of DAH was 62.8%. The unadjusted prevalence of DAH was found to be 64% using the JNC 7 guideline and 62% using the 2017 ACC/AHA guideline. Further analysis and adjusting for age, race/ethnicity and sex shows that the prevalence of DAH is significantly lower in the 2017 ACC/AHA guideline compared to the JNC 7 guideline by nearly 2.15%. There was also a decrease in the unadjusted and adjusted prevalence of DAH after applying the guidelines among all race/ethnicities and by sex, with the use of older guideline resulting in a greater prevalence of depression. Conclusions: With the change in the guidelines for measurement and diagnosis of hypertension, there was significant decrease in the prevalence of DAH. The distribution of the prevalence of DAH between hypertension categories also changed with the current guidelines. Further research into effective screening and management for depression, and future longitudinal follow-up of this population is needed.

s133hospital admissions (0.98; 0.96-0.99). No difference was observed among admissions for ACSCs. ConClusions: These findings suggest MH healthcare is associated with improvements in healthcare utilization rates. Additional healthcare utilization outcomes should be evaluated and further longitudinal analyses, including adjustments for other potential confounders, should be conducted as more MHs are implemented and additional years' data become available.

The relative risk of imrecoxib was collected from randomized controlled trials. Different sceneries of treatment durations and baseline ages were set in the analysis. Results: Over a 6month treatment duration, compared with no treatment, a higher QALYs gained could be found in imrecoxib (0.30), celecoxib (0.27) and diclofenac (0.20). The cost gained per patient was lowest in diclofenac (＄663.38) while highest in imrecoxib (＄912.28). Imrecoxib was a cost-effective option with the ICER of ＄4309 and ＄2489 versus celecoxib and diclofenac, respectively. A similar result could be found in a 12month and 24-month treatment duration. In Chinese OA patients aged $65 years, the ICER was ＄3856 and ＄2738 for imrecoxib versus celecoxib and diclofenac, respectively, over a 6-month treatment duration. Conclusions: With the gross domestic product/capita in Chinese in 2018 was ＄10407, the imrecoxib can be a costeffective option over different treatment durations in Chinese OA patients.

No abstract